Immunotherapies for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Immunotherapies for hepatocellular carcinoma

Published:2021-11-11 Issue: Volume: Page:
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Llovet Josep M.^ORCID,Castet Florian,Heikenwalder Mathias,Maini Mala K.^ORCID,Mazzaferro Vincenzo,Pinato David J.,Pikarsky Eli^ORCID,Zhu Andrew X.,Finn Richard S.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://www.nature.com/articles/s41571-021-00573-2.pdf

Reference216 articles.

1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 71, 209–249 (2021).

2. Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021). This paper provides a comprehensive overview of the epidemiology, pathogenesis and management of HCC.

3. Villanueva, A. Hepatocellular Carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).

4. Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293–313 (2021).

5. Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15, 599–616 (2018).

Cited by 926 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell and Bulk Transcriptomic Analyses Reveal a Stemness and Circadian Rhythm Disturbance-related Signature Predicting Clinical Outcome and Immunotherapy Response in Hepatocellular Carcinoma;Current Gene Therapy;2025-04

2. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy;Biomaterials;2025-02

3. LiverSCA: A comprehensive and user-friendly cell atlas in human hepatocellular carcinoma;Computational and Structural Biotechnology Journal;2024-12

4. Therapeutic potential of tLyp-1-EV-shCTCF in inhibiting liver cancer stem cell self-renewal and immune escape via SALL3 modulation in hepatocellular carcinoma;Translational Oncology;2024-11

5. Constructing and validating pan-apoptosis-related features for predicting prognosis and immunotherapy response in hepatocellular carcinoma;Biochemical and Biophysical Research Communications;2024-11